awmsg logo



aripiprazole (Abilify®)


Reference No. 27

Publication date:
04/08/2009


Appraisal information

aripiprazole (Abilify®) 5 mg tablet
aripiprazole (Abilify®) 10 mg tablet
aripiprazole (Abilify®) 15 mg tablet
aripiprazole (Abilify®) 30 mg tablet


Company: Otsuka Pharmaceutical (UK) Ltd
BNF category: Central nervous system
NMG meeting date: 20/05/2009
AWMSG meeting date: 24/06/2009
   
   
Submission Type: Full Submission
Status: Recommended
Advice No: 1209
Ministerial ratification: 22/07/2009

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

Aripiprazole (Abilify®) is recommended as an option for use within NHS Wales for the treatment of moderate to severe manic episodes in Bipolar I Disorder and for the prevention of a new manic episode in patients who experienced predominantly manic episodes and whose manic episodes responded to aripiprazole treatment. Aripiprazole (Abilify®) may be suitable for shared care when used for long term treatment (i.e. prevention of manic episode) after hospital initiation.
Final Appraisal Recommendation (FAR)
Download